- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
New glaucoma treatment being marketed
A new adjunctive treatment (Diamox, X-GEN Pharmaceuticals) is being marketed for open-angle glaucoma, secondary glaucoma, and preoperatively acute angle-closure glaucoma where delay of surgery is desired in order to lower IOP.
Big Flats, NY-A new adjunctive treatment (Diamox, X-GEN Pharmaceuticals) is being marketed for open-angle glaucoma, secondary glaucoma, and preoperatively acute angle-closure glaucoma where delay of surgery is desired in order to lower IOP.
The treatment is supplied as a sterile, preservative-free lyophilized powder. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide. It is packaged in single-vial cartons NDC# 39822-0190-1 and should be stored at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature].
"Currently, there is only one supplier of acetazolamide for injection USP. Our launch of this product will ensure consistent supply and steady, competitive price levels. We look forward to serving the health-care community as the preferred source for acetazolamide for injection USP," said Susan Badia, X-GEN president and chief executive officer.
